It’s mid-April and the world is embracing the new normal. There is a lot of work being done to combat the COVID19 pandemic both on the frontlines by health workers and healthcare systems and in the background too as scientists and researchers work to find a vaccine or a way to mitigate the effects at least. Life too goes on outside of that and this week we bring you news stories that are not directly related to COVID-19.

Sign up for the Industry Watch newsletter and never miss a story again.

Yes, sign me up
AIDSVu Releases Landmark County-Level Data and Interactive Maps on PrEP Use Across the U.S.

AIDSVu Releases Landmark County-Level Data and Interactive Maps on PrEP Use Across the U.S.

AIDSVu have announced the release of new interactive county-level data and maps visualizing PrEP use from 2012 to 2018, showing a 39 percent increase in PrEP use across the U.S. from 2017 to 2018, continuing a trend of consistent growth in PrEP use since 2012.

Read more
Early Study of RDEB Gene Therapy Using SkinGun as Delivery Vehicle

Early Study of RDEB Gene Therapy Using SkinGun as Delivery Vehicle

SkinGun, a device designed to gently spray stem cells onto the skin of severe burn victims, is being tested in an early study of a potential gene therapy for people with recessive dystrophic epidermolysis bullosa (RDEB). The preclinical work, underway at King’s College London, is exploring RenovaCare’s SkinGun in applying cells genetically engineered to promote skin healing.

Read more
The French pediatric cohort of Castleman disease: a retrospective report of 23 patients

The French pediatric cohort of Castleman disease: a retrospective report of 23 patients

A retrospective report of 23 pediatric patients has been carried out in France. The report was carried out to help set up a national registry aiming to improve CD early recognition, treatment and follow-up, within the context of a new national reference center.

Read more
Switching on a key cancer gene could provide first curative treatment for heart disease

Switching on a key cancer gene could provide first curative treatment for heart disease

Researchers trying to turn off a gene that allows cancers to spread have discovered that by making the gene overactive and functional in the hearts of mice, they have triggered heart cell regeneration. Since adult hearts cannot usually repair themselves once damaged, harnessing the power of this gene represents major progress towards the first curative treatment for heart disease.

Read more
Aspirin linked to reduction in risk of several cancers of the digestive tract

Aspirin linked to reduction in risk of several cancers of the digestive tract

The largest and most comprehensive analysis to date of the link between aspirin and digestive tract cancers has been published. The analysis has found reductions in the risk of cancers such as bowel cancer, pancreatic and liver cancers of between 22% and 38%.

Read more
Yale test of immunotherapy drug for advanced lung cancer shows promise

Yale test of immunotherapy drug for advanced lung cancer shows promise

Researchers at Yale Cancer Center(YCC) have found that use of the checkpoint inhibitor pembrolizumab in place of radiation can extend life with very few side effects in the advanced lung cancer patient population. The study specifically tested the benefit of the treatment in a prospective clinical trial of lung cancer patients who had not yet been treated for brain metastasis or whose tumors recurred after radiation.

Read more
Study of infant gliomas shows that existing drug treatments can be effective without chemotherapy.

Study of infant gliomas shows that existing drug treatments can be effective without chemotherapy.

An aggressive type of brain tumour in infants and children, called high-grade glioma, could be successfully treated with targeted drugs instead of chemotherapy. The study, believed to be the largest of infant gliomas to date, found that these tumours are molecularly different from those in older children, helping explain why they tend to be less aggressive. Clinical trials to assess these are now open.

Read more

You have challenges. We have solutions.

Start a conversation